» Articles » PMID: 25664170

A Review of Creatine Supplementation in Age-related Diseases: More Than a Supplement for Athletes

Overview
Journal F1000Res
Date 2015 Feb 10
PMID 25664170
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Creatine is an endogenous compound synthesized from arginine, glycine and methionine. This dietary supplement can be acquired from food sources such as meat and fish, along with athlete supplement powders. Since the majority of creatine is stored in skeletal muscle, dietary creatine supplementation has traditionally been important for athletes and bodybuilders to increase the power, strength, and mass of the skeletal muscle. However, new uses for creatine have emerged suggesting that it may be important in preventing or delaying the onset of neurodegenerative diseases associated with aging. On average, 30% of muscle mass is lost by age 80, while muscular weakness remains a vital cause for loss of independence in the elderly population. In light of these new roles of creatine, the dietary supplement's usage has been studied to determine its efficacy in treating congestive heart failure, gyrate atrophy, insulin insensitivity, cancer, and high cholesterol. In relation to the brain, creatine has been shown to have antioxidant properties, reduce mental fatigue, protect the brain from neurotoxicity, and improve facets/components of neurological disorders like depression and bipolar disorder. The combination of these benefits has made creatine a leading candidate in the fight against age-related diseases, such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, long-term memory impairments associated with the progression of Alzheimer's disease, and stroke. In this review, we explore the normal mechanisms by which creatine is produced and its necessary physiology, while paying special attention to the importance of creatine supplementation in improving diseases and disorders associated with brain aging and outlining the clinical trials involving creatine to treat these diseases.

Citing Articles

Assessing Creatine-Related Gene Expression in Kidney Disease: Can Available Data Give Insights into an Old Discussion?.

Medeiros M, Abreu B, Lima J Nutrients. 2025; 17(4).

PMID: 40004980 PMC: 11858045. DOI: 10.3390/nu17040651.


Elucidating the Antiglycation Effect of Creatine on Methylglyoxal-Induced Carbonyl Stress In Vitro.

Koike S, Mitsuhashi H, Kishida A, Ogasawara Y Int J Mol Sci. 2024; 25(20).

PMID: 39456665 PMC: 11506949. DOI: 10.3390/ijms252010880.


Fueling the Firefighter and Tactical Athlete with Creatine: A Narrative Review of a Key Nutrient for Public Safety.

Gonzalez D, Forbes S, Zapp A, Jagim A, Luedke J, Dickerson B Nutrients. 2024; 16(19).

PMID: 39408252 PMC: 11478539. DOI: 10.3390/nu16193285.


Detection of sex-specific glutamate changes in subregions of hippocampus in an early-stage Alzheimer's disease mouse model using GluCEST MRI.

Soni N, Swain A, Juul H, Cao Q, Haris M, Wolk D Alzheimers Dement. 2024; 20(10):7124-7137.

PMID: 39262197 PMC: 11485308. DOI: 10.1002/alz.14190.


Mini-encyclopedia of mitochondria-relevant nutraceuticals protecting health in primary and secondary care-clinically relevant 3PM innovation.

Golubnitschaja O, Kapinova A, Sargheini N, Bojkova B, Kapalla M, Heinrich L EPMA J. 2024; 15(2):163-205.

PMID: 38841620 PMC: 11148002. DOI: 10.1007/s13167-024-00358-4.


References
1.
Rae C, Digney A, McEwan S, Bates T . Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial. Proc Biol Sci. 2003; 270(1529):2147-50. PMC: 1691485. DOI: 10.1098/rspb.2003.2492. View

2.
Strong M, Rosenfeld J . Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003; 4(3):136-43. DOI: 10.1080/14660820310011250. View

3.
Groeneveld G, Veldink J, van der Tweel I, Kalmijn S, Beijer C, de Visser M . A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003; 53(4):437-45. DOI: 10.1002/ana.10554. View

4.
Menzies S, Hoff J, Betz A . Middle cerebral artery occlusion in rats: a neurological and pathological evaluation of a reproducible model. Neurosurgery. 1992; 31(1):100-6; discussion 106-7. DOI: 10.1227/00006123-199207000-00014. View

5.
Landwehrmeyer G, McNeil S, Dure 4th L, Ge P, Aizawa H, Huang Q . Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals. Ann Neurol. 1995; 37(2):218-30. DOI: 10.1002/ana.410370213. View